Movatterモバイル変換

[0]ホーム

Jump to content

Oxelumab

Italiano

Edit links

From Wikipedia, the free encyclopedia

This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources.
Find sources: "Oxelumab" – news ·newspapers ·books ·scholar ·JSTOR(January 2024)

Monoclonal antibody

Pharmaceutical compound

Oxelumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	OX-40 ligand
Clinical data
ATC code	none
Identifiers
CAS Number	1186098-83-8^N
ChemSpider	none
UNII	67GFR7JCMN
Chemical and physical data
Formula	C₆₄₂₄H₉₉₂₀N₁₇₀₄O₂₀₁₄S₄₂
Molar mass	144594.46 g·mol⁻¹
^NY (what is this?) (verify)

Oxelumab is a human monoclonal antibody targetingOX40L designed for the treatment ofasthma.^[1]^[2]

Oxelumab was developed byGenentech and co-developed byRoche.

References

[edit]

^"Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab"(PDF).American Medical Association. Archived fromthe original(PDF) on 12 May 2013.
^Brennan FR (2014). "B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders". In Dübel S, Reichert JM (eds.).Handbook of Therapeutic Antibodies. pp. 1079–1114 (1093).doi:10.1002/9783527682423.ch33.ISBN 978-3-527-32937-3.

Monoclonal antibodies for theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Oxelumab&oldid=1324063842"

Categories:

Hidden categories:

[8]ページ先頭